September 2026 brings a substantial Belgian reimbursement update, with relevant patient access changes across oncology, pulmonary arterial hypertension, rare diseases, transplantation, dermatology, neurology and hepatology.
This overview highlights the main changes, without going into the full reimbursement detail.
Oncology and hematology
Breyanzi β lisocabtagene maraleucel β receives first reimbursement for selected adults with relapsed or refractory large B-cell lymphoma.
This introduces another reimbursed CD19 CAR-T option in Belgium. Commercialisation also starts on 1 September, so reimbursement and practical access begin at the same time.
Vyloy β zolbetuximab β becomes reimbursed for eligible patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
It is used in combination with chemotherapy in the first-line setting and adds a new biomarker-defined treatment option for this patient group.
Pulmonary arterial hypertension
Tresuvi β treprostinil β receives first reimbursement for selected patients with severe pulmonary arterial hypertension.
The new route includes defined advanced PAH settings. The product is reimbursed from 1 September but is not yet commercially available.
Adcirca β tadalafil β gains broader reimbursement in paediatric pulmonary arterial hypertension.
A paediatric oral formulation becomes reimbursed, while access to tadalafil tablets is also extended to younger patients. This creates a more continuous pathway across age groups and formulations.
Adempas β riociguat β extends reimbursement from adults to eligible paediatric patients with pulmonary arterial hypertension.
The existing specialist and disease-related requirements remain, but a new younger patient group can now access reimbursed treatment.
Rare diseases
Amvuttra β vutrisiran β gains reimbursement for adults with transthyretin amyloidosis with cardiomyopathy.
This expands its reimbursed role beyond hereditary ATTR polyneuropathy and creates a new option for eligible patients with ATTR cardiomyopathy.
Trientine β Cuprior and Trientine Tillomed β sees broader reimbursement wording in Wilson disease.
The underlying Wilson disease eligibility remains unchanged. Trientine Tillomed is newly listed for reimbursement but is not yet commercially available on 1 September 2026.
Transplantation and infectious diseases
Prevymis β letermovir β gains extended reimbursement for CMV prevention after allogeneic stem-cell transplantation.
Selected high-risk adult patients can now receive an additional period of reimbursed prophylaxis after the initial course.
Gardasil 9 β human papillomavirus vaccine β remains reimbursed for eligible transplant patients, with a timing change for solid-organ transplantation.
For solid-organ transplant patients, reimbursed vaccination now takes place before transplantation rather than afterwards. Vaccination after stem-cell transplantation remains covered.
Dermatology
Tremfya β guselkumab β extends reimbursement to children and adolescents with moderate-to-severe plaque psoriasis.
A transition route is available for patients who were already receiving treatment before the change.
Neurology
Dysport β abobotulinumtoxin A β gains broader reimbursement for adults with focal ankle spasticity.
Access is no longer limited to spasticity after stroke or traumatic brain injury. Patients with other underlying causes may now also qualify.
The September update also includes broad harmonisation across several multiple sclerosis medicines. For these products, access remains materially stable.
Hepatology
Bifiteral β lactulose β exits reimbursement for hepatic insufficiency and cirrhosis from 1 September 2026.
No replacement reimbursement route was identified.
Market access read-out
September 2026 combines new reimbursements, paediatric extensions and selected access restrictions.
For clinicians and access teams, the most relevant changes are in large B-cell lymphoma, gastric cancer, pulmonary arterial hypertension, ATTR cardiomyopathy, paediatric plaque psoriasis, focal spasticity and hepatic insufficiency/cirrhosis.